OakChart

Becton Dickinson & Co

BDXHealthcare·Medical Instruments & Supplies·USA·Large·NYSE·Nov 11 • 9:20 AM ET

208.52-4.09 (-1.92%)
2026-11-11 15:21 CET
Market cap
57,912.20 USD m
Revenue, TTM
20,223.00 USD m
Net income, TTM
1,144.00 USD m
Free cash flow, TTM
2,693.00 USD m
EPS diluted, TTM
4.14
P/E
50.39
Compare

Price

BDX against its 20, 50 and 200-day averages
2050200miss
140.00160.00180.00200.00220.006.1M12.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BDXclose 208.5220-day 200.7150-day 189.64200-day 167.87208.52

3.8% under 216.74 on 9 Nov 2026. Last 15 sessions, 11.8% high to low

Profile

BDX
52-week range, 89% of the way up
140.11216.74

Becton, Dickinson & Co. is a global medical technology company, which engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, instruments, and reagent systems to detect infectious diseases, healthcare-associated infections, and cancers. The BD Interventional segment offers vascular, urology, oncology, and surgical specialty products to hospitals, ambulatory surgery centers, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via its Homecare business. The company was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

IndexS&P 500, RUI
Employees72000
IPOSep 25, 1963
Beta0.21
ATR, 14d4.66
Rel volume0.02
Short float2.98%
Insider own0.20%
Inst own99.11%

Snapshot

6 groups

Valuation

IndexS&P 500, RUI
Market Cap56.80B
Enterprise Value72.13B
Income1.14B
Sales20.22B
Book/sh89.64
Cash/sh3.73
Dividend Est.4.10 (1.97%)
Dividend TTM3.98 (1.91%)
Dividend Ex-DateDec 10, 2026
Dividend Gr. 3/5Y4.89% 4.81%
Payout102.68%
Employees72000
IPOSep 25, 1963

Ratios

P/E50.39
Forward P/E14.66
PEG2.31
P/S2.81
P/B2.33
P/C55.85
P/FCF21.09
EV/EBITDA9.97
EV/Sales3.57
Quick Ratio0.54
Current Ratio0.87
Debt/Eq0.66
LT Debt/Eq0.54
Option/ShortYes / Yes

Earnings

EPS (ttm)4.14
EPS next Y14.23
EPS next Q2.35
EPS this Y4.37%
EPS next Y7.33%
EPS next 5Y6.34%
EPS past 3/5Y-6.08% -9.81%
Sales past 3/5Y0.15% 0.34%
EPS Y/Y TTM-28.89%
Sales Y/Y TTM-7.40%
EPS Q/Q47.91%
Sales Q/Q-10.46%
EarningsNov 05 BMO
EPS/Sales Surpr.2.02% 3.14%

Ownership

Insider Own0.20%
Insider Trans-2.70%
Inst Own99.11%
Inst Trans-3.61%
ROA2.81%
ROE5.96%
ROIC3.02%
Gross Margin55.95%
Oper. Margin16.12%
Profit Margin5.66%
SMA203.89%
SMA509.96%
SMA20024.22%
Trades-

Technical

Shs Outstand272.39M
Shs Float271.83M
Short Float2.98%
Short Ratio4.53
Short Interest8.11M
52W High216.74 -3.79%
52W Low140.11 48.83%
Volatility3.19% 2.19%
ATR (14)4.66
RSI (14)63.71
Beta0.21
Rel Volume0.02
Avg Volume1.79M
Volume1,409

Performance

Perf Week-0.32%
Perf Month11.29%
Perf Quarter14.59%
Perf Half Y44.63%
Perf YTD36.73%
Perf Year40.38%
Perf 3Y13.08%
Perf 5Y11.09%
Perf 10Y59.76%
Recom2.16
Target Price226.23
Prev Close212.61
Price208.52
Change %-1.92%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Nov 06, 2026UpgradeWWells FargoEqual Weight → Overweight$242+16.1%
Oct 20, 2026InitiatedWWolfe ResearchOutperform
Jul 28, 2026InitiatedUUBSBuy$19-90.9%
May 04, 2026ResumedEEvercore ISIOutperform$180-13.7%
Apr 10, 2026ResumedGGoldmanNeutral$167-19.9%
Feb 10, 2026ResumedBBarclaysOverweight$202-3.1%
Feb 03, 2026ResumedCCitigroupBuy$233+11.7%
Sep 25, 2025InitiatedRRBC Capital MktsSector Perform$211+1.2%
May 22, 2025DowngradeCCitigroupBuy → Neutral$185-11.3%
May 02, 2025DowngradeRRaymond JamesOutperform → Mkt Perform

Peers

Mkt cap
TickerCompanyMkt cap
BAXBaxter International Inc13.63B
TFXTeleflex Incorporated6.06B
ICUIICU Medical Inc4.59B
MDLNMedline Inc52.96B
WSTWest Pharmaceutical Services Inc28.87B
SOLVSolventum Corp15.10B
STVNStevanato Group Spa3.69B
BSXBoston Scientific Corp64.05B
MDTMedtronic Plc128.68B
OMCLOmnicell Inc1.68B

Insider trading

latest 14 of 52
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Roland GoetteOfficerNov 10 '26Proposed Sale213.951,855396,868Nov 10 05:37 PM
Polen Thomas E JrChairman, CEO and PresidentNov 05 '26Option Exercise178.9420,2393,621,567130,402Nov 09 05:44 PM
Polen Thomas E JrChairman, CEO and PresidentNov 05 '26Sale210.002,993628,530110,163Nov 09 05:44 PM
THOMAS POLENDirectorNov 05 '26Proposed Sale209.192,993626,106Nov 05 04:29 PM
Feld MichaelEVP, Chief Revenue OfficerOct 26 '26Sale198.137615,05819,568Oct 27 02:27 PM
MICHAEL FELDOfficerOct 26 '26Proposed Sale198.917615,117Oct 26 04:28 PM
Feld MichaelEVP, Chief Revenue OfficerSep 28 '26Sale183.707613,96119,644Sep 29 09:13 PM
MICHAEL FELDOfficerSep 28 '26Proposed Sale183.827613,970Sep 28 04:21 PM
Feld MichaelEVP, Chief Revenue OfficerAug 26 '26Sale188.4916531,10119,720Aug 27 04:28 PM
MICHAEL FELDOfficerAug 26 '26Proposed Sale189.7816531,314Aug 26 04:17 PM
RICHARD BYRDFormer OfficerAug 20 '26Proposed Sale187.971,330249,993Aug 20 04:13 PM
Polen Thomas E JrChairman, CEO and PresidentAug 13 '26Option Exercise167.2543,2787,238,246153,441Aug 14 04:36 PM
Polen Thomas E JrChairman, CEO and PresidentAug 13 '26Sale185.004,152768,120110,163Aug 14 04:36 PM
THOMAS POLENDirectorAug 13 '26Proposed Sale183.584,152762,224Aug 13 04:32 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VOOVanguard S&P 500 ETFAUM: 1054.75B
VOVanguard Morningstar Mid-Cap ETFAUM: 107.07B
IVViShares Core S&P 500 ETFAUM: 871.38B
SPYSPDR S&P 500 ETF TrustAUM: 793.23B
VTVVanguard Morningstar Value ETFAUM: 196.23B
XLVState Street Health Care Select Sector SPDR ETFAUM: 50.35B
VOEVanguard Morningstar Mid-Cap Value ETFAUM: 24.66B
VIGVanguard Dividend Appreciation FTFAUM: 117.07B
SDYState Street SPDR S&P Dividend ETFAUM: 22.68B

News

latest 14 of 206
  • BD to Host Investor Day on December 10, 2026 (PR Newswire)
  • BD reports FY26 revenues of $19.5bn after medtech prioritisation (Medical Device Network)
  • BD Ends Its Transformation Year With Its Strongest Quarter, But A Modest FY27 Guide Tests A Stock Priced For Momentum (Earnings Whispers)
  • Becton Dickinson: Fiscal Q4 Earnings Snapshot (Associated Press)
  • BD Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results (PR Newswire)
  • Loading…
  • BD Board Increases Dividend for 55th Consecutive Year, Authorizes 10 Million Additional Share Repurchases (PR Newswire)
  • BD Names Bridget Bagnato Worldwide President of Peripheral Intervention (PR Newswire) +5.56%
  • BD Must Hit A Steep Fourth-Quarter Margin Target As Alaris Comparison Toughens (Earnings Whispers)
  • BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options (PR Newswire)
  • Is Boston Scientific Stock Riskier Than It Was A Year Ago? (Trefis)
  • What Could BSX Stock Be Worth In Three Years? (Trefis)
  • BD to Announce Financial Results for its Fourth Quarter and Full Year of Fiscal 2026 (PR Newswire)
  • BD and Global Health Leaders Call for Accelerated Maternal Life Saving Measures Worldwide (PR Newswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q42026-11-054.1504.0682.5205,2745,11314
2026Q32026-08-063.2303.1411.3704,9834,88711
2026Q22026-05-072.9002.778-1.1084,7144,67213
2026Q12026-02-092.2872.2101.3364,4865,14710
2025Q42025-11-063.9603.9191.7175,8905,90611
2025Q32025-08-073.6803.4011.9985,5095,48610
2025Q22025-05-013.3503.2801.0705,2725,35312
2025Q12025-02-053.4302.9781.0435,1685,10012
2024Q42024-11-073.8103.7681.4495,4375,38014
2024Q32024-08-013.5003.3091.6785,0575,07714
2024Q22024-05-023.1702.9691.8505,0455,03813
2024Q12024-02-012.6802.4000.9644,7064,73212
2023Q42023-11-093.4203.4250.3695,0875,02013
2023Q32023-08-032.9602.9131.3614,8784,83914
2023Q22023-05-042.8602.7431.5334,8214,68913
2023Q12023-02-022.9802.6761.7034,5864,52913

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2020FY9.9449.6782.71617,11716,819
2021FY12.75212.5996.85420,24820,016
2022FY11.35011.3305.87818,87018,815
2023FY12.21012.2274.93819,37219,302
2024FY13.14013.1125.85920,17820,170
2025FY11.31611.3005.81621,84021,858
2026FY12.70012.6725.06019,45719,295
2027FY-13.255--19,764
2028FY-14.226--20,597
2029FY-15.272--21,438
2030FY-16.260--22,041
2031FY-17.420--22,905

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2027Q1S2026-11-0610064,5044,4624,566
2027Q1S2026-11-0510054,5124,4624,572
2027Q1S2026-10-209004,5754,5414,595
2027Q1S2026-10-169014,5754,5414,595
2027Q1S2026-09-308014,5804,5504,595
2027Q1S2026-08-118014,5794,5504,595
2027Q1S2026-08-068014,5804,5504,599
2027Q1S2026-07-277004,5954,5644,620
2027Q1S2026-07-146004,5944,5644,620
2027Q1S2026-07-137014,5864,5434,620
2027Q1S2026-07-107014,5894,5624,620
2027Q1S2026-06-127014,5894,5624,620
2027Q1S2026-05-267014,5914,5624,620
2027Q1S2026-05-077014,5904,5514,620

Estimate history

EPS, annual0.63.9382.7166.8545.8784.9385.8595.8164.09
Period201820192020202120222023202420252026
EPS, quarterly1.4491.0431.071.9981.7171.336-1.1081.372.54
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Sales, annual159831621816074191311887019372201782184019457
Period201820192020202120222023202420252026
Sales, quarterly543751685272550958905252471449835274
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26
Shares, annual268.224270.427290.017284.476283.357290.392289.101285.402-272.386
Period201820192020202120222023202420252026MRQ
Shares, quarterly289.101287.135286.607286.627285.402284.742275.54272.386-
PeriodQ4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26Q4 '26

Income statement, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Total Revenue20,223.0019,457.0021,840.0020,178.0019,372.0018,870.0019,131.0016,074.0016,218.00
Cost of Goods Sold Incl. D&A8,909.0010,243.0011,915.0011,053.0011,202.0010,393.0010,500.009,276.008,720.00
Gross Profit11,314.009,214.009,925.009,125.008,170.008,477.008,631.006,798.007,498.00
Selling, General and Administrative Excl. Other6,188.005,953.006,543.006,047.005,965.005,965.005,998.005,224.005,189.00
Research and Development1,059.00988.001,265.001,190.001,237.001,256.001,279.001,039.001,004.00
Other Operating Expense126.00199.002.00-9.009.00-4.000.000.000.00
Operating Income5,000.003,062.003,380.003,087.002,196.002,516.002,633.001,574.002,309.00
Interest Expense564.00564.00613.00528.00452.00398.00469.00528.00639.00
Unusual Expense810.00806.00-5,005.00676.00339.00264.00737.00299.00480.00
Net Income Before Taxes1,887.001,805.001,881.002,005.001,662.001,783.001,692.00414.00591.00
Income Taxes398.00388.00203.00300.00132.00148.0088.0062.00-141.00
Consolidated Net Income1,492.001,417.001,678.001,705.001,530.001,635.001,604.00352.00733.00
Net Income From Continuing Operations1,492.001,417.001,678.001,705.001,530.001,635.001,604.00352.00733.00
Net Income1,144.001,145.001,678.001,705.001,424.001,689.002,002.00767.001,082.00
EPS (Recurring)6.246.11-6.337.485.766.528.623.465.16
EPS (Basic, Before Extraordinaries)4.154.115.835.884.975.936.922.754.01
EPS (Diluted)4.144.095.825.864.945.886.852.723.94
EBITDA7,238.005,300.005,694.005,231.004,357.004,618.004,724.003,728.004,562.00
Non-Operating Income (Expense)1.00113.00-5,891.00122.00257.00-67.00265.00-333.00-599.00
Other After Tax Adjustments--0.000.000.000.000.000.000.00
Stock Option Compensation Expense--202.00191.00203.00185.00183.00188.00203.00
Price To Earnings Ratio51.3851.3826.4538.9836.7929.2327.5065.3149.69
Price To Sales Ratio2.432.582.473.483.853.393.754.094.29
Gross Margin55.9547.3645.4445.2242.1744.9245.1242.2946.23
Operating Margin16.1215.7415.4815.3011.3413.3313.769.7914.24
Net Margin5.665.887.688.457.358.9510.464.776.67
Shares Outstanding--285.40289.10290.39283.36284.48290.02270.43
Market Capitalization57,912.2057,912.2042,159.5454,764.6958,940.6149,941.1054,088.7451,675.0852,319.30

Income statement, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q32025Q22025Q1
Total Revenue5,274.004,983.004,714.005,252.005,890.005,509.005,272.005,168.00
Cost of Goods Sold Incl. D&A2,581.002,668.002,560.002,841.003,092.002,875.003,015.002,933.00
Gross Profit2,693.002,315.002,154.002,411.002,798.002,634.002,257.002,235.00
Selling, General and Administrative Excl. Other1,508.001,519.001,462.001,699.001,688.001,617.001,575.001,661.00
Research and Development246.00258.00249.00306.00322.00297.00302.00343.00
Other Operating Expense76.0012.0026.0012.00229.007.0035.0028.00
Operating Income1,109.00784.00666.00700.00881.001,010.00647.00546.00
Interest Expense130.00132.00149.00153.00155.00152.00151.00155.00
Unusual Expense77.0089.00533.00111.00-3,124.0097.0090.0092.00
Net Income Before Taxes901.00554.0039.00393.00510.00703.00363.00306.00
Income Taxes209.00102.0076.0011.0017.00129.0055.003.00
Consolidated Net Income696.00451.00-37.00382.00493.00574.00308.00303.00
Net Income From Continuing Operations696.00451.00-37.00382.00493.00574.00308.00303.00
Net Income696.00377.00-311.00382.00493.00574.00308.00303.00
EPS (Recurring)2.741.600.221.61-5.902.231.291.27
EPS (Basic, Before Extraordinaries)2.551.37-1.111.341.722.001.071.05
EPS (Diluted)2.541.37-1.111.341.722.001.071.04
EBITDA1,650.001,348.001,229.001,314.001,362.001,628.001,255.001,153.00
Non-Operating Income (Expense)-1.00-9.0055.00-44.00-3,341.00-59.00-43.007.00
Other After Tax Adjustments-0.000.000.000.000.000.000.00
Stock Option Compensation Expense---71.8945.8243.4577.9071.10
Price To Earnings Ratio51.3838.3725.6826.1626.4525.8329.9030.01
Price To Sales Ratio2.432.002.072.532.462.313.163.19
Gross Margin51.0646.4645.6945.9147.5047.8142.8143.25
Operating Margin21.0315.7314.1313.3314.9618.3312.2710.57
Net Margin13.207.57-6.607.278.3710.425.845.86
Shares Outstanding-272.39275.54284.74285.40286.63286.61287.14
Market Capitalization57,912.2041,697.4744,769.9843,451.5842,159.5438,796.1451,686.5951,704.64

Balance sheet, annual

Currency USD, millions
Metric2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Cash & Short Term Investments1,017.00859.002,301.001,489.001,167.002,404.002,937.00620.001,253.00
Short Term Receivables2,771.002,994.003,033.002,534.002,191.002,350.002,398.002,345.002,319.00
Inventories3,191.003,894.003,843.003,273.003,224.002,743.002,743.002,579.002,451.00
Other Current Assets1,337.001,508.001,291.001,380.001,559.001,341.00891.001,120.001,388.00
Total Current Assets8,317.009,255.0010,468.008,676.008,141.008,838.008,969.006,664.007,411.00
Net Property, Plant & Equipment6,191.007,882.007,697.007,074.006,494.006,449.006,341.005,659.005,375.00
Total Investments and Advances-0.000.000.000.000.000.000.000.00
Intangible Assets33,624.0036,017.0037,382.0035,469.0036,931.0036,659.0037,433.0038,354.0040,041.00
Deferred Tax Assets-1,740.00---1,343.00---
Other Assets2,659.00431.001,739.001,561.001,368.001,920.001,269.001,088.001,077.00
Total Assets50,791.0055,325.0057,286.0052,780.0052,934.0053,866.0054,012.0051,765.0053,904.00
Short Term Debt Incl. Current Port. of LT Debt2,923.001,695.002,312.001,258.002,297.00626.00813.001,309.002,601.00
Accounts Payable-1,974.001,896.001,641.001,699.001,739.001,355.001,092.001,106.00
Income Tax Payable-329.00168.00139.00157.00178.00144.00140.00343.00
Other Current Liabilities6,620.004,314.004,580.003,602.003,658.004,083.003,524.003,114.003,166.00
Total Current Liabilities9,543.008,312.008,956.006,640.007,811.006,626.005,836.005,655.007,216.00
Long Term Debt13,422.0018,325.0018,607.0015,152.0014,270.0017,454.0017,560.0018,081.0018,894.00
Provision for Risks Charges944.001,069.00942.001,023.00902.001,228.001,435.001,272.001,056.00
Deferred Tax Liabilities-1,771.002,067.002,450.002,674.002,684.00---
Other Liabilities2,200.00458.00824.001,718.001,995.002,197.005,416.005,676.005,744.00
Total Liabilities26,109.0029,935.0031,396.0026,983.0027,652.0030,189.0030,247.0030,684.0032,910.00
Non-Equity Reserves-0.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.002.002.002.002.002.00
Common Equity24,682.0025,390.0025,890.0025,797.0025,280.0023,675.0023,763.0021,079.0020,992.00
Total Shareholders Equity24,682.0025,390.0025,890.0025,797.0025,282.0023,677.0023,765.0021,081.0020,994.00
Accumulated Minority Interest-0.000.000.000.000.000.000.000.00
Total Equity24,682.0025,390.0025,890.0025,797.0025,282.0023,677.0023,765.0021,081.0020,994.00
Total Liabilities & Stockholders Equity50,791.0055,325.0057,286.0052,780.0052,934.0053,866.0054,012.0051,765.0053,904.00
Book Value Per Share-88.9689.5588.8489.2283.2281.9477.9578.26
Tangible Book Value Per Share--37.24-39.75-33.31-41.12-45.64-47.14-63.88-71.02
Full-Time Employees-72,00074,00073,00077,00075,00072,00070,09376,032
Price to Book Ratio2.371.662.122.271.962.262.182.492.51
Return on Assets2.672.983.102.893.062.970.671.390.68
Return on Equity5.666.546.605.996.686.761.573.481.83
Return on Invested Capital3.013.843.833.624.505.092.113.150.78
Quick Ratio0.540.640.740.810.630.921.070.720.69
Current Ratio0.871.111.171.311.041.331.541.181.03

Cash flow, annual

Currency USD, millions
MetricTTM2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Net Income1,145.001,145.001,678.001,705.001,530.001,635.001,604.00874.001,233.00
Depreciation2,238.002,238.002,462.002,286.002,288.002,229.002,230.002,154.002,253.00
Other Funds (Non Cash)32.0032.00257.00202.00258.00428.00765.00700.00594.00
Funds from Operations3,415.003,415.003,923.003,982.003,454.004,172.004,298.003,426.003,699.00
Extraordinary Item--0.000.000.000.000.000.000.00
Changes in Working Capital-50.00-50.00-493.00-184.00-465.00-1,538.00349.00113.00-369.00
Cash from Operating Activities3,365.003,365.003,430.003,798.002,989.002,634.004,647.003,539.003,330.00
Capital Expenditures-672.00-672.00-760.00-725.00-874.00-973.00-1,194.00-810.00-957.00
Net Assets From Acquisitions-22.00-22.000.00-3,924.000.00-2,070.00-508.00-164.000.00
Sale of Fixed Assets and Businesses--0.000.00540.000.000.000.00477.00
Purchase or Sale of Investments20.0020.00422.00-421.000.000.000.000.000.00
Purchase of Investments--0.00-421.000.000.000.000.000.00
Sale Or Maturity of Investments20.0020.00422.000.000.000.000.000.000.00
Other Uses-335.00-335.00-480.00-444.00-382.00-189.00-179.00-258.00-261.00
Other Sources38.0038.000.000.000.002.001.000.000.00
Cash from Investing Activities-972.00-972.00-818.00-5,514.00-716.00-3,230.00-1,880.00-1,232.00-741.00
Cash Dividends Paid-1,161.00-1,161.00-1,196.00-1,100.00-1,114.00-1,082.00-1,048.00-1,026.00-984.00
Change in Capital Stock-2,433.00-2,433.00-1,000.00-500.000.00-500.00-1,750.002,917.000.00
Repurchase of Common Pref Stock-2,433.00-2,433.00-1,000.00-500.000.00-500.00-1,750.000.000.00
Sale of Common Pref Stock--0.000.000.000.000.002,917.000.00
Proceedsfrom Stock Options--0.000.000.000.000.002,917.000.00
Issuance or Reduction of Debt, Net-2,414.00-2,414.00-1,334.003,775.00-722.00-78.00-243.00-1,760.00-2,035.00
Change in Long Term Debt-1,992.00-1,992.00-1,789.003,375.00-492.00-308.00-243.00-1,275.00-2,520.00
Issuance of Long Term Debt704.00704.000.004,517.001,662.00497.004,869.003,389.002,224.00
Reduction of Long Term Debt-2,696.00-2,696.00-1,789.00-1,142.00-2,154.00-805.00-5,112.00-4,664.00-4,744.00
Net Financing Active Other Cash Flow3,841.003,841.00-87.00-88.00-120.001,069.00-265.00-109.00-204.00
Other Financing Activities Uses-75.00-75.00-87.00-88.00-120.00-342.00-265.00-109.00-205.00
Cash from Financing Activities-2,167.00-2,167.00-3,617.002,087.00-1,956.00-591.00-3,306.0022.00-3,223.00
Exchange Rate Effect7.007.000.004.005.00-45.0015.00-3.00-12.00
Net Change in Cash234.00234.00-1,005.00375.00322.00-1,232.00-524.002,326.00-646.00
Free Cash Flow2,693.002,693.002,670.003,073.002,115.001,661.003,453.002,729.002,373.00
Preferred Dividends (Cash Flow)--0.000.00--90.00-90.00--
Price to Free Cash Flow32.0232.7136.6435.5674.48110.5929.8638.5850.04
Deferred Taxes & Investment Tax Credit---474.00-211.00-622.00-120.00-301.00-302.00-381.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Cash & Short Term Investments1,017.00864.001,018.001,035.00859.00819.00
Short Term Receivables2,771.002,364.002,205.002,508.002,994.002,943.00
Inventories3,191.003,316.003,358.004,085.003,894.003,950.00
Other Current Assets1,337.001,595.001,432.001,560.001,508.001,285.00
Total Current Assets8,317.008,139.008,012.009,189.009,255.008,997.00
Net Property, Plant & Equipment6,191.006,083.006,082.006,972.007,882.006,818.00
Total Investments and Advances-0.000.000.000.000.00
Intangible Assets33,624.0033,965.0034,304.0035,645.0036,017.0036,385.00
Deferred Tax Assets----1,740.00-
Other Assets2,659.002,546.002,434.003,035.00431.002,702.00
Total Assets50,791.0050,731.0050,832.0054,841.0055,325.0054,902.00
Short Term Debt Incl. Current Port. of LT Debt2,923.003,297.002,573.002,623.001,695.001,810.00
Accounts Payable-5,773.005,597.006,138.001,974.006,350.00
Income Tax Payable----329.00-
Other Current Liabilities6,620.00334.00337.000.004,314.000.00
Total Current Liabilities9,543.009,404.008,507.008,761.008,312.008,160.00
Long Term Debt13,422.0013,511.0014,706.0016,916.0018,325.0017,531.00
Provision for Risks Charges944.001,005.001,026.001,067.001,069.00908.00
Deferred Tax Liabilities----1,771.00-
Other Liabilities2,200.002,394.002,460.002,815.00458.002,831.00
Total Liabilities26,109.0026,314.0026,699.0029,559.0029,935.0029,430.00
Non-Equity Reserves-0.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity24,682.0024,416.0024,133.0025,282.0025,390.0025,472.00
Total Shareholders Equity24,682.0024,416.0024,133.0025,282.0025,390.0025,472.00
Accumulated Minority Interest-0.000.000.000.000.00
Total Equity24,682.0024,416.0024,133.0025,282.0025,390.0025,472.00
Total Liabilities & Stockholders Equity50,791.0050,730.0050,832.0054,841.0055,325.0054,902.00
Book Value Per Share-89.6487.5888.7988.9688.87
Tangible Book Value Per Share--35.06-36.91-36.39-37.24-38.07
Full-Time Employees----72,000-
Price to Book Ratio2.371.731.771.711.661.54
Return on Assets2.812.442.683.212.982.91
Return on Equity5.965.175.726.966.546.26
Return on Invested Capital1.840.99-0.800.911.131.33
Quick Ratio0.540.510.550.580.640.62
Current Ratio0.870.870.941.051.111.10

Cash flow, quarterly

Currency USD, millions
Metric2026Q42026Q32026Q22026Q12025Q42025Q3
Net Income696.00377.00-310.00382.00493.00574.00
Depreciation541.00563.00520.00614.00629.00618.00
Other Funds (Non Cash)-389.00-89.00463.0047.00-106.00-74.00
Funds from Operations966.00777.00600.001,072.00797.001,123.00
Extraordinary Item-0.000.000.000.000.00
Changes in Working Capital492.00-125.00-2.00-415.00557.0096.00
Cash from Operating Activities1,458.00652.00598.00657.001,354.001,219.00
Capital Expenditures-296.00-143.00-125.00-108.00-352.00-174.00
Net Assets From Acquisitions0.00-22.000.000.000.000.00
Sale of Fixed Assets and Businesses-0.000.000.000.00-13.00
Purchase or Sale of Investments-7.004.0023.000.0014.00-5.00
Purchase of Investments-0.000.000.000.000.00
Sale Or Maturity of Investments-7.004.0023.000.0014.00-5.00
Other Uses-103.00-68.00-89.00-75.00-156.00-144.00
Other Sources38.000.000.000.000.000.00
Cash from Investing Activities-369.00-228.00-192.00-183.00-494.00-336.00
Cash Dividends Paid-286.00-286.00-290.00-299.00-297.00-299.00
Preferred Dividends (Cash Flow)-0.000.000.000.000.00
Change in Capital Stock-183.000.00-2,000.00-250.00-250.000.00
Repurchase of Common Pref Stock-183.000.00-2,000.00-250.00-250.000.00
Sale of Common Pref Stock-0.000.000.000.000.00
Proceedsfrom Stock Options-0.000.000.000.000.00
Issuance or Reduction of Debt, Net-459.00-283.00-1,989.00317.00-258.00-540.00
Change in Long Term Debt0.008.00-2,000.000.00-580.00-333.00
Issuance of Long Term Debt0.00704.000.000.000.000.00
Reduction of Long Term Debt0.00-696.00-2,000.000.00-580.00-333.00
Net Financing Active Other Cash Flow57.00-81.003,934.00-69.00-4.00-2.00
Other Financing Activities Uses-2.00-10.006.00-69.00-4.00-2.00
Cash from Financing Activities-871.00-651.00-343.00-302.00-809.00-841.00
Exchange Rate Effect2.002.001.002.002.009.00
Net Change in Cash148.00-152.0064.00174.0053.0051.00
Free Cash Flow1,162.00509.00473.00549.001,002.001,045.00
Price to Free Cash Flow32.0230.5923.4238.5836.4635.96

Revenue breakdown

Asia2025: 3.09B
Consolidation, Policy2025: 1.00M
EMEA2025: 4.73B
Other countries2025: 1.23B
United States2025: 12.79B
Interventional2025: 5.22B
Life Sciences2025: 5.17B
Medical2025: 11.46B

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.98%8.1M271.8M1.75M
2026-10-153.28%8.9M271.8M1.77M
2026-09-303.60%9.8M271.8M1.80M
2026-09-154.16%11.3M271.8M2.10M
2026-08-313.93%10.7M271.8M2.16M
2026-08-143.45%9.4M271.8M2.39M
2026-07-313.68%10.0M271.8M2.66M
2026-07-153.78%10.4M274.9M2.91M
2026-06-304.09%11.2M274.9M3.00M
2026-06-152.65%7.3M274.8M2.75M
2026-05-292.62%7.2M275.0M2.86M
2026-05-153.06%8.4M275.0M2.86M
2026-04-302.32%6.4M275.0M2.95M
2026-04-152.54%7.2M284.2M2.84M
2026-03-313.34%9.5M284.2M2.78M
2026-03-134.04%11.5M284.2M2.85M
2026-02-274.85%13.8M284.2M2.75M
2026-02-135.12%14.6M284.2M2.75M
2026-01-302.35%6.7M284.4M2.19M
2026-01-152.13%6.1M284.4M2.21M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call95.000.000.000.00-0.000.00---
call1000.000.000.00-0.000.00---
call1050.000.000.00-0.000.00---
call1100.000.000.00-0.000.00---
call1150.000.000.00-0.000.00---
call1200.000.000.00-0.000.00---
call1250.000.000.00-0.000.00---
call1300.000.000.00-0.000.00---
call1350.000.000.00-0.000.00---
call1400.000.000.00-0.000.00---
call1450.000.000.00-0.000.00---
call1500.000.0066.40-3.000.00---
call1550.000.000.00-0.000.00---
call1600.000.000.00-0.000.00---
call1650.000.0031.78-2.000.00---
call1700.000.0029.27-11.000.00---
call1750.000.0015.40-8.000.00---
call1800.000.0033.35-12.000.00---
call1850.000.0012.75-1530.00---
call1900.000.0023.81-5200.00---
call1950.000.0019.04-71.000.00---
call2000.000.0014.36-1100.00---
call2100.000.006.10-3610.00---
call2200.000.001.50-4210.00---
call2300.000.000.28-62.000.00---
call2400.000.000.20-48.000.00---
call2500.000.000.00-0.000.00---
call2600.000.000.00-0.000.00---
call2700.000.000.00-0.000.00---
put95.000.000.000.00-0.000.00---
put1000.000.000.00-0.000.00---
put1050.000.000.00-0.000.00---
put1100.000.000.00-0.000.00---
put1150.000.000.00-0.000.00---
put1200.000.000.00-0.000.00---
put1250.000.000.00-0.000.00---
put1300.000.000.00-0.000.00---
put1350.000.000.15-30.000.00---
put1400.000.000.00-0.000.00---
put1450.000.000.16-3.000.00---
put1500.000.000.18-13.000.00---
put1550.000.001.79-11.000.00---
put1600.000.000.88-51.000.00---
put1650.000.001.06-38.000.00---
put1700.000.000.40-3340.00---
put1750.000.000.08-81.000.00---
put1800.000.000.55-66.000.00---
put1850.000.000.25-12.000.00---
put1900.000.000.38-4080.00---
put1950.000.000.40-2440.00---
put2000.000.000.50-10.000.00---
put2100.000.002.25-1,0520.00---
put2200.000.009.50-2.000.00---
put2300.000.0017.50-2.000.00---
put2400.000.000.00-0.000.00---
put2500.000.000.00-0.000.00---
put2600.000.000.00-0.000.00---
put2700.000.000.00-0.000.00---

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-094Statement of changes in beneficial ownership of securities2026-11-05SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-274Statement of changes in beneficial ownership of securities2026-10-26SEC
2026-10-26144Filing for proposed sale of securities under Rule 144.SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-28144Filing for proposed sale of securities under Rule 144.SEC
2026-09-034Statement of changes in beneficial ownership of securities2026-09-02SEC
2026-08-274Statement of changes in beneficial ownership of securities2026-08-26SEC
2026-08-26144Filing for proposed sale of securities under Rule 144.SEC
2026-08-244Statement of changes in beneficial ownership of securities2026-08-20SEC
2026-08-20144Filing for proposed sale of securities under Rule 144.SEC
2026-08-144Statement of changes in beneficial ownership of securities2026-08-13SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-11SEC
2026-08-11144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-064Statement of changes in beneficial ownership of securities2026-08-06SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-06SCHEDULE 13GSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-03144Filing for proposed sale of securities under Rule 144.SEC
2026-07-284Statement of changes in beneficial ownership of securities2026-07-27SEC
2026-07-27144Filing for proposed sale of securities under Rule 144.SEC
2026-07-228-KCurrent report2026-07-19SEC
2026-07-064Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-06-2911-KAnnual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)2025-12-31SEC
2026-06-2911-KAnnual reports of employee stock purchase, savings and similar plans pursuant to Section 15(d)2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-1100628.53K1
2026-100015.06K1
2026-090013.96K1
2026-08001.24M3
2026-070011.78K1
2026-0600742.83K4
2026-050011.05K1
2026-040011.24K1
2026-030011.76K1
2026-0200187.67K2
2026-0100349.21K2
2025-1200152.31K3
2025-110038.32K1

Institutional holders

Manager% owned
BlackRock, Inc.8.93%
VANGUARD CAPITAL MANAGEMENT LLC6.53%
STATE STREET CORP5.44%
VANGUARD PORTFOLIO MANAGEMENT LLC5.43%
First Eagle Investment Management, LLC5.10%
Invesco Ltd.3.23%
MASSACHUSETTS FINANCIAL SERVICES CO /MA/3.14%
GEODE CAPITAL MANAGEMENT, LLC2.97%
FRANKLIN RESOURCES INC2.54%
WELLINGTON MANAGEMENT GROUP LLP2.31%

Funds

Fund% owned
First Trust Enhanced Short Maturity ETF9.07%
VANGUARD INTERMEDIATE-TERM INVESTMENT-GRADE FUND9.02%
VANGUARD INTERMEDIATE-TERM CORPORATE BOND INDEX FUND8.23%
VANGUARD SHORT-TERM INVESTMENT-GRADE FUND7.13%
Columbia Select Corporate Income Fund6.60%
Invesco BulletShares 2027 Corporate Bond ETF6.51%
VANGUARD SHORT-TERM CORPORATE BOND INDEX FUND6.51%
Baird Aggregate Bond Fund5.44%
Columbia Variable Portfolio - Select Corporate Income Fund4.71%
iShares iBonds Dec 2027 Term Corporate ETF4.49%

OakChart. BDX. Cached 15 minutes.